Crystallographic Structure of the Human Leukocyte Antigen DRA, DRB3*0101: Models of a Directional Alloimmune Response and Autoimmunity

Journal of Molecular Biology

Volumn 371, Issue 2, 2007, Pages 435-446

  Parry, Christian S ^a   Gorski, Jack ^b   Stern, Lawrence J ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

blood disorders of the newborn; complementary binding specificity; DR3 DR52 haplotype; fetal maternal incompatibility; platelet integrin dimorphism

Indexed keywords

HETERODIMER; LEUKOCYTE ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANONICAL ANALYSIS; CRYSTALLOGRAPHY; HAPLOTYPE; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE;

EID: 34447255464     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.05.025     Document Type: Article

References (63)

1. Benacerraf B. The role of MHC gene products in immune regulation. Science 212 (1981) 1229-1238
2. Zinkernagel R.M., and Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248 (1974) 701-702
3. von Boehmer H. Positive selection of lymphocytes. Cell 76 (1994) 219-228
4. Nossal G.J.V. Negative selection of lymphocytes. Cell 76 (1994) 229-239
5. Reusch T.B., Haberli M.A., Aeschlimann P.B., and Milinski M. Female sticklebacks count alleles in a strategy of sexual selection explaining MHC polymorphism. Nature 414 (2001) 300-302
6. Penn D.J., Damjanovich K., and Potts W.K. MHC heterozygosity confers a selective advantage against multiple-strain infections. Proc. Natl Acad. Sci. USA 99 (2002) 11260-11264
7. Gorski J., and Mach B. Polymorphism of human Ia antigens: gene conversion between two DR beta loci results in a new HLA-D/DR specificity. Nature 322 (1986) 67-70
8. Texier C., Pouvelle-Moratille S., Busson M., Charron D., Menez A., and Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31 (2001) 1837-1846
9. Li Y., Li H., Martin R., and Mariuzza R.A. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J. Mol. Biol. 304 (2000) 177-188
10. Newman P.J., Derbes R.S., and Aster R.H. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83 (1989) 1778-1781
11. Goldberger A., Kolodziej M., Poncz M., Bennett J.S., and Newman P.J. Effect of single amino acid substitutions on the formation of the PlA and Bak alloantigenic epitopes. Blood 78 (1991) 681-687
12. Shulman N.R., Aster R.H., Leitner A., and Hiller M.C. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in "autoimmunity". J. Clin. Invest. 40 (1961) 1597-1620
13. West K.A., Anderson D.R., McAlister V.C., Hewlett T.J., Belitsky P., Smith J.W., and Kelton J.G. Alloimmune thrombocytopenia after organ transplantation. New Engl. J. Med. 341 (1999) 1504-1507
14. Wu S., Maslanka K., and Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J. Immunol. 158 (1997) 3221-3226
15. Kaplan C. Immune thrombocytopenia in the foetus and the newborn:diagnosis and therapy. Transfus. Clin. Biol. 8 (2001) 311-314
16. Castle V., Andrew M., Kelton J., Giron D., Johnston M., and Carter C. Frequency and mechanism of neonatal thrombocytopenia. J. Pediatr. 108 (1986) 749-755
17. Ahya R., Turner M.L., and Urbaniak S.J. Fetomaternal alloimmune thrombocytopenia. Transfus. Apher. Sci. 25 (2001) 139-145
18. Kim H.O., Jin Y., Kickler T.S., Blakemore K., Kwon O.H., and Bray P.F. Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion 35 (1995) 863-867
19. Lefkovits J., Plow E.F., and Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New Engl. J. Med. 332 (1995) 1553-1559
20. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., and Wiley D.C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364 (1993) 33-39
21. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., and Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368 (1994) 215-221
22. Smith K.J., Pyrdol J., Gauthier L., Wiley D.C., and Wucherpfennig K.W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188 (1998) 1511-1520
23. Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., and Wiley D.C. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl Acad. Sci. USA 93 (1996) 734-738
24. Dessen A., Lawrence C.M., Cupo S., Zaller D.M., and Wiley D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7 (1997) 473-481
25. Murthy V.L., and Stern L.J. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure 5 (1997) 1385-1396
26. Watson D.C., Reim J., and Dintzis H.M. Suppresion of the antibody response to a polymorphic peptide from the platelet alloantigen integrin beta 3 with low molecular weight antigen arrays. J. Immunol. 156 (1996) 2443-2450
27. Newton-Nash D.K., and Eckels D.D. Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides. J. Immunol. 150 (1993) 1813-1821
28. Geluk A., Bloemhoff W., De Vries R.R., and Ottenhoff T.H. Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. Eur. J. Immunol. 22 (1992) 107-113
29. Malcherek G., Falk K., Rotzschke O., Rammensee H.G., Stevanovic S., Gnau V., et al. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int. Immunol. 5 (1993) 1229-1237
30. Geluk A., Fu X.T., van Meijgaarden K.E., Jansen Y.Y., De Vries R.R., Karr R.W., and Ottenhoff T.H. T cell receptor and peptide-contacting residues in the HLA-DR17(3) beta 1 chain. Eur. J. Immunol. 24 (1994) 3241-3244
31. Ghosh P., Amaya M., Mellins E., and Wiley D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378 (1995) 457-462
32. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuerici O., Sahin U., et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual class II matrices. Nature Biotech. 17 (1999) 555-561
33. Fremont D.H., Hendrickson W.A., Marrack P., and Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science 272 (1996) 1001-1004
34. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature Biotechnol. 17 (1999) 555-561
35. Geluk A., van Meijgaarden K.E., Southwood S., Oseroff C., Drijfhout J.W., de Vries R.R., et al. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152 (1994) 5742-5748
36. Sidney J., Oseroff C., Southwood S., Wall M., Ishioka G., Koning F., and Sette A. DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles. J. Immunol. 149 (1992) 2634-2640
37. Chicz R.M., Urban R.G., Gorga J.C., Vignali D.A., Lane W.S., and Strominger J.L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178 (1993) 27-47
38. O'Sullivan D., Sidney J., Appella E., Walker L., Phillips L., Colon S.M., et al. Characterization of the specificity of peptide binding to four DR haplotypes. J. Immunol. 145 (1990) 1799-1808
39. O'Sullivan D., Sidney J., Del Guercio M.F., Colon S.M., and Sette A. Truncation analysis of several DR binding epitopes. J. Immunol. 146 (1991) 1240-1246
40. Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J., Vignal D.A., and Strominger J.L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358 (1992) 764-768
41. Nagvekar N., Corlett L., Jacobson L.W., Matsuo H., Chalkley R., Driscoll P.C., et al. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol. 162 (1999) 4079-4087
42. Hill M., Beeson D., Moss P., Jacobson L., Bond A., Corlett L., et al. Early-onset myasthenia gravis: a recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann. Neurol. 45 (1999) 224-231
43. Todd J.A., Bell J.I., and McDevitt H.O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329 (1987) 599-604
44. Quartey-Papafio R., Lund T., Chandler P., Picard J., Ozegbe P., Day S., et al. Aspartate at position 57 of nonobese diabetic I-Ag7 beta-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. J. Immunol. 154 (1995) 5567-5575
45. Lee K.H., Wucherpfennig K.W., and Wiley D.C. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nature Immunol. 2 (2001) 501-507
46. Corper A.L., Stratmann T., Apostolopoulos V., Scott C.A., Garcia K.C., Kang A.S., et al. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288 (2000) 505-511
47. Latek R., Suri A., Petzold S.J., Nelson C.A., Kanagawa O., Unanue E.R., and Fremont D.H. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II mlecule of NOD mice. Immunity 12 (2000) 610-699
48. Gregori S., Bono E., Gallazzi F., Hammer J., Harrison L.C., and Adorini L. The motif for peptide binding to the insulin-dependent diabetes mellitus-associated class II MHC molecule I-Ag7 validated by phage display library. Int. Immunol. 12 (2000) 493-503
49. Stratmann T., Apostolopoulos V., Mallet-Designe V., Corper A.L., Scott C.A., Wilson I.A., et al. The I-Ag7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder. J. Immunol. 165 (2000) 3214-3225
50. Chao C.C., Sytwu H.K., Chen E.L., Toma J., and McDevitt H.O. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc. Natl Acad. Sci. USA 96 (1999) 9299-9304
51. Stern L.J., and Wiley D.C. The human class II MHC protein HLA-DR1 assembles as empty beta heterodilers in the absence of antigenic peptide. Cell 68 (1992) 465-477
52. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
53. Navaza J. Implementation of molecular replacement in Amore. Acta Crystallog. sect. D 57 (2001) 1367-1372
54. Collaborative Computational Project, N. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D 50 (1994) 760-763
55. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D 54 (1998) 901-921
56. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
57. Potterton E., Briggs P., Turkenburg M., and Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallog. sect. D 59 (2003) 1131-1137
58. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D 53 (1997) 240-255
59. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallog. sect. D 60 (2004) 2126-2132
60. Perrakis A., Sixma T.K., Wilson K.S., and Lamzin V.S. wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models. Acta Crystallog. sect. D 53 (1997) 448-455
61. Lovell S.C., Davis I.W., Arendall W.B.r., de Bakker P.I., Word J.M., Prisant M.G., et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins: Struct. Funct. Genet. 50 (2003) 437-450
62. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004) 1605-1612
63. Humphrey, W., Dalke, A. & Schulten, K. (1996). VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-8, 27-8.